<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.dmsjournal.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Diabetology &amp; Metabolic Syndrome - Most accessed articles</title>
        <link>http://www.dmsjournal.com</link>
        <description>The most accessed research articles published by Diabetology &amp; Metabolic Syndrome</description>
        <dc:date>2010-02-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/13" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/11" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/1/1/10" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/1/1/17" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/1/1/19" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/3" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/5" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/1/1/27" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/1" />
                                <rdf:li rdf:resource="http://www.dmsjournal.com/content/2/1/12" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/13">
        <title>Short-term nutritional counseling reduces body mass index, waist circumference, triceps skinfold and triglycerides in women with metabolic syndrome</title>
        <description>Background:
It is recognized that the growing epidemic of metabolic syndrome is related to dietary and lifestyle changes.ObjectiveThe purpose of this study was to evaluate short-term application of nutritional counseling in women with metabolic syndrome.
Methods:
This follow-up study was conducted from September to November 2008 with thirty three women &#8805;35 years old screened clinically for nutritional counseling. Dietary intake was reported, and biochemical and body composition measures were taken at baseline and after three months of follow-up.
Results:
Of the 33 women evaluated, 29 patients completed the study. The prevalence of type 2 diabetes mellitus, hypertension, dyslipidemia, and obesity was high at 38%, 72.4%, 55.2%, and 75.8%, respectively. At the end of three-months of follow-up, a significant decline in body mass index, waist circumference, triceps skinfold, and triglycerides was observed, as was an increase in calcium and vitamin D intake. The multiple regression analysis showed that changes in body mass index, triceps skinfold, waist circumference and triglyceride levels after nutritional intervention were positively associated with changes in anthropometric (loss of body weight) and biochemical (decrease of TG/HDL-c ratio) parameters. Moreover, waist circumference changes were negatively associated with changes in calcium and vitamin D intake.
Conclusion:
Short-term nutritional counseling improved some factors of metabolic syndrome. Moreover, the increases in calcium and vitamin D consumption can be associated with the improvement in markers of metabolic syndrome.</description>
        <link>http://www.dmsjournal.com/content/2/1/13</link>
                <dc:creator>Gustavo Pimentel</dc:creator>
                <dc:creator>Silvia Arimura</dc:creator>
                <dc:creator>Bruno Moura</dc:creator>
                <dc:creator>Maria Silva</dc:creator>
                <dc:creator>Maysa de Sousa</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:13</dc:source>
        <dc:date>2010-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-13</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2010-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/11">
        <title>Insulin resistance and triglyceride/hdlc index are strongly associated with coronary artery disease</title>
        <description>Background:
Insulin-resistance is associated with cardiovascular disease but it is not used as a marker for disease in clinical practice.AimsTo study the association between the homeostatic model assessment (HOMA-IR) and triglyceride/HDLc ratio (TG/HDLc) with the presence of coronary artery disease in patients submitted to cardiac catheterization.
Methods:
In a cross-sectional study, 131 patients (57.0 &#177; 10 years-old, 51.5% men) underwent clinical, laboratory and angiographic evaluation and were classified as No CAD (absence of coronary artery disease) or CAD (stenosis of more than 30% in at least one major coronary artery).
Results:
Prevalence of coronary artery disease was 56.7%. HOMA-IR and TG/HDLc index were higher in the CAD vs No CAD group, respectively: HOMA-IR: 3.19 (1.70-5.62) vs. 2.33 (1.44-4.06), p = 0.015 and TG/HDLc: 3.20 (2.38-5.59) vs. 2.80 (1.98-4.59) p = 0.045) - median (p25-75). After a ROC curve analysis, cut-off values were selected based on the best positive predictive value for each variable: HOMA-IR = 6.0, TG/HDLc = 8.5 and [HOMA-IR&#215;TG/HDLc] = 28. Positive predictive value for coronary artery disease for HOMA-IR&gt;6.0 was 82.6%, for TG/HDLc&gt;8.5 was 85.7% and for [HOMA-IR&#215;TG/HDLc]&gt;28 was 88.0%. Adjusted relative risk (age, gender, diabetes, body mass index, systolic blood pressure) for the presence of coronary artery disease was: for HOMA-IR&gt;6.0, 1.47 (95.CI: 1.06-2.04, p = 0.027), for TG/HDLc&gt;8.5, 1.46 (95% CI:1.07-1.98), p = 0.015) and for [HOMA-IR &#215; TG/HDLc] &gt;28, 1.64 (95%CI: 1.28-2.09), p &lt; 0.001).
Conclusions:
Increased HOMA-IR, TG/HDLc and their product are positively associated with angiographic coronary artery disease, and may be useful for risk stratification as a high-specificity test for coronary artery disease.</description>
        <link>http://www.dmsjournal.com/content/2/1/11</link>
                <dc:creator>Marcello Bertoluci</dc:creator>
                <dc:creator>Alexandre Quadros</dc:creator>
                <dc:creator>Rogerio Sarmento-Leite</dc:creator>
                <dc:creator>Beatriz Schaan</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:11</dc:source>
        <dc:date>2010-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-11</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2010-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/1/1/10">
        <title>Diabetic nephropathy</title>
        <description>Diabetic nephropathy is the leading cause of chronic renal disease and a major cause of cardiovascular mortality. Diabetic nephropathy has been categorized into stages: microalbuminuria and macroalbuminuria. The cut-off values of micro- and macroalbuminuria are arbitrary and their values have been questioned. Subjects in the upper-normal range of albuminuria seem to be at high risk of progression to micro- or macroalbuminuria and they also had a higher blood pressure than normoalbuminuric subjects in the lower normoalbuminuria range. Diabetic nephropathy screening is made by measuring albumin in spot urine. If abnormal, it should be confirmed in two out three samples collected in a three to six-months interval. Additionally, it is recommended that glomerular filtration rate be routinely estimated for appropriate screening of nephropathy, because some patients present a decreased glomerular filtration rate when urine albumin values are in the normal range. The two main risk factors for diabetic nephropathy are hyperglycemia and arterial hypertension, but the genetic susceptibility in both type 1 and type 2 diabetes is of great importance. Other risk factors are smoking, dyslipidemia, proteinuria, glomerular hyperfiltration and dietary factors. Nephropathy is pathologically characterized in individuals with type 1 diabetes by thickening of glomerular and tubular basal membranes, with progressive mesangial expansion (diffuse or nodular) leading to progressive reduction of glomerular filtration surface. Concurrent interstitial morphological alterations and hyalinization of afferent and efferent glomerular arterioles also occur. Podocytes abnormalities also appear to be involved in the glomerulosclerosis process. In patients with type 2 diabetes, renal lesions are heterogeneous and more complex than in individuals with type 1 diabetes. Treatment of diabetic nephropathy is based on a multiple risk factor approach, and the goal is retarding the development or progression of the disease and to decrease the subject&apos;s increased risk of cardiovascular disease. Achieving the best metabolic control, treating hypertension (&lt;130/80 mmHg) and dyslipidemia (LDL cholesterol &lt;100 mg/dl), using drugs that block the renin-angiotensin-aldosterone system, are effective strategies for preventing the development of microalbuminuria, delaying the progression to more advanced stages of nephropathy and reducing cardiovascular mortality in patients with diabetes.</description>
        <link>http://www.dmsjournal.com/content/1/1/10</link>
                <dc:creator>Themis Zelmanovitz</dc:creator>
                <dc:creator>Fernando Gerchman</dc:creator>
                <dc:creator>Amely Balthazar</dc:creator>
                <dc:creator>Fulvio Thomazelli</dc:creator>
                <dc:creator>Jorge Matos</dc:creator>
                <dc:creator>Luis Canani</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2009, 1:10</dc:source>
        <dc:date>2009-09-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-1-10</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-09-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/1/1/17">
        <title>Effect of Carnitine and herbal mixture extract on obesity induced by high fat diet in rats</title>
        <description>Background:
Obesity-associated type 2 diabetes is rapidly increasing throughout the world. It is generally recognized that natural products with a long history of safety can modulate obesity.AimTo investigate the development of obesity in response to a high fat diet (HFD) and to estimate the effect of L-carnitine and an Egyptian Herbal mixture formulation (HMF) (consisting of T. chebula, Senae, rhubarb, black cumin, aniseed, fennel and licorice) on bodyweight, food intake, lipid profiles, renal, hepatic, cardiac function markers, lipid Peroxidation, and the glucose and insulin levels in blood and liver tissue in rats.MethodWhite male albino rats weighing 80-90 gm, 60 days old. 10 rats were fed a normal basal diet (Cr), 30 rats fed a high-fat diet (HFD) for 14 weeks during the entire study. Rats of the HFD group were equally divided into 3 subgroups each one include 10 rats. The first group received HFD with no supplement (HFD), the 2nd group HFD+L-carnitine and the third group received HFD+HMF. Carnitine and HMF were administered at 10th week (start time for treatments) for 4 weeks.Body weight, lipid profile &amp; renal function (urea, uric acid creatinine) ALT &amp; AST activities, cardiac markers, (LDH, C.K-NAC and MB) the oxidative stress marker reduced glutathione (GSH), and Malondialdehyde (MDA) catalase activity, in addition to glucose, insulin, and insulin resistance in serum &amp; tissues were analyzed.
Results:
Data showed that feeding HFD diet significantly increased final body weight, triglycerides (TG), total cholesterol, &amp; LDL concentration compared with controls, while significantly decreasing HDL; meanwhile treatment with L-carnitine, or HMF significantly normalized the lipid profile.Serum ALT, urea, uric acid, creatinine, LDH, CK-NAC, CK-MB were significantly higher in the high fat group compared with normal controls; and administration of L-carnitine or herbal extract significantly lessened the effect of the HFD. Hyperglycemia, hyperinsulinemia, and high insulin resistance (IR) significantly increased in HFD in comparison with the control group. The treatment with L-carnitine or HMF improved the condition. HFD elevated hepatic MDA and lipid peroxidation associated with reduction in hepatic GSH and catalase activity; whereas administration of L-carnitine or herbal extract significantly ameliorated these hepatic alterations.
Conclusion:
HFD induced obesity associated with a disturbed lipid profile, defective antioxidant stability, and high values of IR parameters; this may have implications for the progress of obesity related problems. Treatment with L-carnitine, or HMF extract improved obesity and its associated metabolic problems in different degrees. Also HMF has antioxidant, hypolipidaemic insulin sensitizing effects. Moreover HMF might be a safe combination on the organs whose functions were examined, as a way to surmount the obesity state; and it has a distinct anti-obesity effect.</description>
        <link>http://www.dmsjournal.com/content/1/1/17</link>
                <dc:creator>Kamal Amin</dc:creator>
                <dc:creator>Mohamed Nagy</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2009, 1:17</dc:source>
        <dc:date>2009-10-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-1-17</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2009-10-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/1/1/19">
        <title>Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials 

</title>
        <description>Stem cell therapy is one of the most promising treatments for the near future. It is expected that this kind of therapy can ameliorate or even reverse some diseases. With regard to type 1 diabetes, studies analyzing the therapeutic effects of stem cells in humans began in 2003 in the Hospital das Cl&#237;nicas of the Faculty of Medicine of Ribeir&#227;o Preto - SP USP, Brazil, and since then other centers in different countries started to randomize patients in their clinical trials. Herein we summarize recent data about beta cell regeneration, different ways of immune intervention and what is being employed in type 1 diabetic patients with regard to stem cell repertoire to promote regeneration and/or preservation of beta cell mass.The Diabetes Control and Complications Trial (DCCT) was a 7-year longitudinal study that demonstrated the importance of the intensive insulin therapy when compared to conventional treatment in the development of chronic complications in patients with type 1 diabetes mellitus (T1DM). This study also demonstrated another important issue: there is a reverse relationship between C-peptide levels (endogenous indicator of insulin secretion) chronic complications - that is, the higher the C-peptide levels, the lower the incidence of nephropathy, retinopathy and hypoglycemia. From such data, beta cell preservation has become an additional target in the management of T1DM 1.</description>
        <link>http://www.dmsjournal.com/content/1/1/19</link>
                <dc:creator>Carlos Eduardo Barra Couri</dc:creator>
                <dc:creator>Julio Cesar Voltarelli</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2009, 1:19</dc:source>
        <dc:date>2009-10-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-1-19</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2009-10-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/3">
        <title>Buccal Alterations in Diabetes Mellitus </title>
        <description>Long standing hyperglycemia besides damaging the kidneys, eyes, nerves, blood vessels, heart, can also impair the function of the salivary glands leading to a reduction in the salivary flow. When salivary flow decreases, as a consequence of an acute hyperglycemia, many buccal or oral alterations can occur such as: a) increased concentration of mucin and glucose;  b) impaired production and/or action of many antimicrobian factors; c) absence of a metaloprotein called gustin, that contains zinc and is responsible for the constant maturation of taste papillae; d) bad taste; e) oral candidiasis  f) increased  cells exfoliation after contact, because of poor lubrification; g) increased proliferation of pathogenic microorganisms; h) coated tongue; i) halitosis ; and many others may occur as a consequence of chronic hyperglycemia: a) tongue alterations, generally a burning mouth; b) periodontal disease; c) white spots due to demineralization in the teeth; d) caries; e) delayed healing of wounds; f) greater tendency to infections; g) plane lichen; h) mucosa ulcerations. Buccal alterations found in diabetic patients, although not specific of this disease have its incidence and progression increased when an inadequate glycemic control is present.</description>
        <link>http://www.dmsjournal.com/content/2/1/3</link>
                <dc:creator>Carlos Negrato</dc:creator>
                <dc:creator>Olinda Tarzia</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:3</dc:source>
        <dc:date>2010-01-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-3</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-01-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/5">
        <title>The multiple functions of the endocannabinoid system: a focus on the regulation of food intake.</title>
        <description>Background:
Cannabis sativa (also known as marijuana) has been cultivated by man for more than 5,000 years. However, there was a rise in its use in the 20th century for recreational, religious or spiritual, and medicinal purposes. The main psychoactive constituent of cannabis, whose structure was identified in the 1960&apos;s, is &#916;9-tetrahydrocannabinol. On the other hand, the discovery of cannabinoid receptors and their endogenous agonists took place only very recently. In fact, the first cannabinoid receptor (CB1) was cloned in 1990, followed 3 years later by the characterization of a second cannabinoid receptor (CB2). Since the 19th century, the use of cannabis has been reported to stimulate appetite and increase the consumption of sweet and tasty food, sometimes resulting in significant weight gain. The recent description of the endocannabinoid system, not only in the central nervous system but also in peripheral tissues, points to its involvement in the regulation of appetite, food intake and energy metabolism. Consequently, the pharmacological modulation of the over-activity of this system could be useful in the treatment of the metabolic syndrome.
Conclusions:
The endocannabinoid system has important physiological functions not only in the central nervous system but also in peripheral tissues. The activation of central CB1 receptors, particularly in hypothalamic nuclei and in the limbic system, is involved in the regulation of feeding behavior, and especially in the control of the intake of palatable food. In the periphery, cannabinoid receptors are present in adipocytes, skeletal muscle, gastrointestinal tract and liver, modulating energy metabolism.</description>
        <link>http://www.dmsjournal.com/content/2/1/5</link>
                <dc:creator>Eduardo Tibirica</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:5</dc:source>
        <dc:date>2010-01-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-5</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-01-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/1/1/27">
        <title>Resistance exercise training lowers HbA1c more than aerobic training in adults with type 2 diabetes</title>
        <description>Background:
The aim of this study was to compare the effects of 10 weeks of resistance or treadmill exercises on glycemic indices levels prior to and immediately following exercise in adults with type 2 diabetes.Research Design and MethodTwenty inactive subjects (mean age 53.5 years) with type 2 diabetes enrolled in the study. Baseline HbA1c, blood glucose levels, heart rate, and blood pressure were measured for each subject prior to the initiation of the exercise program. Subsequently, subjects were matched to age, waist circumference and sex and assigned to either isocaloric resistance or treadmill exercise groups, which met 3 times per week for 10 weeks.
Results:
Both groups showed a reduction in pre and post-exercise blood glucose and HbA1c values. There was no change in resting blood pressure or heart rate in either group during the course of the 10 week intervention. The group receiving resistance exercises showed significant differences in the daily pre-exercise plasma glucose readings between the beginning and end of the exercise protocol (p &lt; 0.001). There were significant improvements in the mean HbA1c reading pre and post training in both groups (p &lt; 0.001). However, the greater reduction was noted in the resistance exercise group, and at 10 weeks their HbA1c levels were significantly lower than the group that received treadmill exercises (p &lt; 0.006).
Conclusion:
Ten weeks of resistance exercises were associated with a significantly better glycemic control in adults with type 2 diabetes compared to treadmill exercise.</description>
        <link>http://www.dmsjournal.com/content/1/1/27</link>
                <dc:creator>Salameh Bweir</dc:creator>
                <dc:creator>Muhammed Al-Jarrah</dc:creator>
                <dc:creator>Abdul-Majeed Almalty</dc:creator>
                <dc:creator>Mikhled Maayah</dc:creator>
                <dc:creator>Irina Smirnova</dc:creator>
                <dc:creator>Lesya Novikova</dc:creator>
                <dc:creator>Lisa Stehno-Bittel</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2009, 1:27</dc:source>
        <dc:date>2009-12-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-1-27</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>1</prism:volume>
        <prism:startingPage>27</prism:startingPage>
        <prism:publicationDate>2009-12-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/1">
        <title>Prevalence and gender distribution of the metabolic syndrome</title>
        <description>Background:
The Metabolic syndrome (MetS)  is a cardiovascular risk factor of public health significance and of recent has become a topical issue. The prevalence of diabetes mellitus (DM)  is on the increase and with this scenario, a possible increase in burden of DM which may be largely attributed to cardiovascular complications is expected. The objective of this report is to determine the prevalence of the MetS and compare gender characteristics in subjects with type 2 DM.
Methods:
Subjects with type 2 DM were recruited from an urban hospital for the study.  Clinical  data  was obtained by interviewing the patients and referring to their Case folders. The anthropometric indices  and blood pressure measurements were documented. Laboratory parameters analysed for  included total cholesterol, high density and low density cholesterol, triglyceride and glycosylated haemoglobin. Statistical analysis included usage of Student&apos;s t test and chi square.
Results:
963 patients with type 2 DM aged between 35-85 years were recruited for the study. The main outcome measures included the prevalence of the metabolic syndrome and the gender differences of its components. The  prevalence of the metabolic syndrome  was  86% . The frequency of occurrence of  the  MetS was similar for men (83%)  and women (86%) and increased with age in both sexes. The prevalence of MetS  increased from  11% among participants aged 20 through 29 years to  89% in participants aged 70 through 79 . In our patients with DM, the commonest  occurring  and least detected  MetS defining parameters are  central obesity and elevated triglyceride levels respectively. The components of the MetS that differed significantly in both sexes was HDL-C. The combination of the components of the MetS were comparable in both genders and  5.8% of the subjects with the MetS had all components of  the MetS.
Conclusion:
The prevalence of the MetS in type 2DM  is high in both genders  and increases with age thus posing a potential high cardiovascular risk in these group of patients. The modifiable risk factors for the MetS should be a focus point in the management of subjects with type 2 DM,</description>
        <link>http://www.dmsjournal.com/content/2/1/1</link>
                <dc:creator>Anthonia Ogbera</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:1</dc:source>
        <dc:date>2010-01-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-1</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.dmsjournal.com/content/2/1/12">
        <title>Plasma Adrenomedullin level in Egyptian children and Adolescents with type 1 diabetes mellitus: relationship to microvascular complications</title>
        <description>Background:
Adrenomedullin (AM) is known to be elevated in different clinical situations including diabetes mellitus (DM), but its potential role in the pathogenesis of vascular complications in diabetic children and adolescents is to be clarified. Hence, the study aimed at assessment of plasma adrenomedullin levels in children and adolescents with type 1 DM and correlation of these levels with metabolic control and diabetic microvascular complications (MVC).
Methods:
The study was performed in the Diabetes Specialized Clinic, Children&apos;s Hospital of Ain Shams University in Cairo, Egypt. It included 55 diabetic children and adolescents (mean age 13.93 &#177; 3.15 years) who were subdivided into 40 with no MVC and 15 with MVC. Thirty healthy subjects, age-and sex- matched were included as control group (mean age 12.83 &#177; 2.82 years). Patients and controls were assessed for glycosylated hemoglobin (HbA1c) and plasma adrenomedullin assay using ELISA technique.
Results:
Mean plasma AM levels were significantly increased in patients with and without MVC compared to control group, (110.6 pg/mL, 60.25 pg/mL and 39.2 pg/mL respectively) (P &lt; 0.01) with higher levels in those with MVC (P &lt; 0.05). Plasma AM levels were positively correlated with both duration of diabetes (&#961; = 0.703, P &lt; 0.001) and glycemic control (HbA1c) (&#961; = 0.453, P &lt; 0.001).
Conclusion:
Higher plasma AM levels in diabetics particularly in those with MVC &amp; its correlation with diabetes duration and metabolic control may reflect the role of AM in diabetic vasculopathy in the pediatric age group.</description>
        <link>http://www.dmsjournal.com/content/2/1/12</link>
                <dc:creator>Safinaz El Habashy</dc:creator>
                <dc:creator>Randa Matter</dc:creator>
                <dc:creator>Eman El Hadidi</dc:creator>
                <dc:creator>Hala Afifi</dc:creator>
                <dc:source>Diabetology &amp; Metabolic Syndrome 2010, 2:12</dc:source>
        <dc:date>2010-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1758-5996-2-12</dc:identifier>
        <prism:publicationName>Diabetology &amp; Metabolic Syndrome</prism:publicationName>
        <prism:issn>1758-5996</prism:issn>
        <prism:volume>2</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2010-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
